Fenwick & West represented BioAge Labs, Inc., a leading biotechnology company developing medicines to treat aging and age-related diseases, in its exclusive worldwide license agreement with Taisho Pharmaceutical Co., Ltd. to develop and commercialize Taisho's clinical-stage Hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) inhibitor, BGE-117, to ameliorate multiple diseases of aging. Under the agreement, BioAge will make an upfront payment to Taisho, who is entitled to receive development and commercial milestone payments plus royalties based on annual net sales. BioAge will be responsible for all development, manufacturing and commercialization of BGE-117 worldwide while Taisho has an option right for co-commercialization in Japan and several countries in Southeast Asia. More information about BioAge’s license agreement with Taisho can be obtained from the company announcement.
The Fenwick transaction team was led by technology transaction partner Jake Handy and corporate partner Matthew Rossiter.